Anna Meglan

Nov 26, 2024 | biorxiv.org | Juliet Allen |Anna Meglan |Kyle Vaccaro |José Manuel Velarde

AbstractMacrophages hold tremendous promise as effectors of cancer immunotherapy, but the best strategies to provoke these cells to attack tumors remain unknown. Here, we evaluated the therapeutic potential of targeting two distinct macrophage immune checkpoints: CD47 and CD24. We found that antibodies targeting these antigens could elicit maximal levels of phagocytosis when combined together in vitro.